Table 1.

Most frequently used active compounds licensed in Europe in the treatment of LUTS [10,11,15].

Active Compound	Pharmacological Effect	Dose (mg)	Administration	Speed of Onset	Interaction May Occur
Alfuzosin	α1-adrenoceptor antagonist	7.5–10	Immediately following a meal, at the same time each day, depending on the formulation	days	In combination with vasodilators (e.g., PDE5 inhibitors, nitrates), and other antihypertensives. Before cataract surgery, consultation is necessary. In the case of tamsulosin, warfarin and diclofenac co-administration is not recommended.
Doxazosin	α1-adrenoceptor antagonist	2–8 (TR)	IR: daily once at bedtime ER: daily once with the first meal	days
Silodosin	α1-adrenoceptor antagonist	4–8	With a meal, at the same time each day	days
Tamsulosin	α1-adrenoceptor antagonist	0.4–0.8	30 min after the first meal	days
Terazosin	α1-adrenoceptor antagonist	5–20 (TR)	Daily once at bedtime	days
Dutasteride	5α-reductase (type 1 and 2) inhibitor	0.5	Without chewing, at the same time each day	6–12 months	In combination with strong CYP3A4 and CYP2D6 inhibitors.
Finasteride	5α-reductase (type 2) inhibitor	5	Without chewing, at the same time each day	6–12 months	No drug interactions have been identified.
Alfuzosin+ Finasteride	combination therapy	10/5	Swallow 2 different tablets without chewing, after dinner	days	ama
Tamsulosin+ Dutasteride	combination therapy	0.4/0.5	Swallow 1 tablet without chewing, 30 min after a meal, at the same time each day	days	ama

TR: titration recommended, IR: immediate release, ER: extended-release, ama: as mentioned above.